FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004851258> ?p ?o ?g. }

• W2004851258 endingPage "339" @default.
• W2004851258 startingPage "328" @default.
• W2004851258 abstract "Background & Aims Human carbonyl reductase1 (CBR1) has been reported to protect cells against lipid peroxidation. Since human hepatocellular carcinoma (HCC) cells are under oxidative stress in hypoxic conditions, we tested if CBR1 is upregulated by hypoxia inducible factor (HIF)-1α, helps tumor growth under hypoxia, and renders chemoresistance to cisplatin and doxorubicin in HCC. Methods Luciferase, EMSA, and chromatin immunoprecipitation (ChIP) assays were performed to analyze whether HIF-1α transactivates CBR1 promoter. CBR1 overexpression, siRNA, and inhibitors were used to study the role of CBR1 in tumor survival under hypoxia and chemoresistance to cisplatin and doxorubicin in HCC. FACS and Western blot analysis for oxidative stress markers were performed to measure ROS. Immunohistochemistry (IHC) was performed to analyze CBR1 expression in 78 cases of HCC and 123 cases of colon cancer tissues. Results The CBR1 promoter was activated by HIF-1α. CBR1 overexpression enhanced cell survival by decreasing oxidative stress under hypoxia, cisplatin, and doxorubicin treatment. CBR1-siRNA increased apoptosis via increasing oxidative stress. Combinational therapy of CBR1 inhibitors with cisplatin or doxorubicin enhanced cell death in HCC cells. IHC showed CBR1 overexpression in 56 (72%) out of 78 HCC and 88 (72%) out of 123 colon cancer cases. Conclusions Overexpressed CBR1 by HIF-1α plays important roles in tumor growth under hypoxia and chemoresistance to anticancer drugs. The inhibition of CBR1 by specific inhibitors enhances anticancer drug efficacy in HCC. Therefore, we concluded that CBR1 is a good molecular target for the development of anticancer drugs for HCC patients. Human carbonyl reductase1 (CBR1) has been reported to protect cells against lipid peroxidation. Since human hepatocellular carcinoma (HCC) cells are under oxidative stress in hypoxic conditions, we tested if CBR1 is upregulated by hypoxia inducible factor (HIF)-1α, helps tumor growth under hypoxia, and renders chemoresistance to cisplatin and doxorubicin in HCC. Luciferase, EMSA, and chromatin immunoprecipitation (ChIP) assays were performed to analyze whether HIF-1α transactivates CBR1 promoter. CBR1 overexpression, siRNA, and inhibitors were used to study the role of CBR1 in tumor survival under hypoxia and chemoresistance to cisplatin and doxorubicin in HCC. FACS and Western blot analysis for oxidative stress markers were performed to measure ROS. Immunohistochemistry (IHC) was performed to analyze CBR1 expression in 78 cases of HCC and 123 cases of colon cancer tissues. The CBR1 promoter was activated by HIF-1α. CBR1 overexpression enhanced cell survival by decreasing oxidative stress under hypoxia, cisplatin, and doxorubicin treatment. CBR1-siRNA increased apoptosis via increasing oxidative stress. Combinational therapy of CBR1 inhibitors with cisplatin or doxorubicin enhanced cell death in HCC cells. IHC showed CBR1 overexpression in 56 (72%) out of 78 HCC and 88 (72%) out of 123 colon cancer cases. Overexpressed CBR1 by HIF-1α plays important roles in tumor growth under hypoxia and chemoresistance to anticancer drugs. The inhibition of CBR1 by specific inhibitors enhances anticancer drug efficacy in HCC. Therefore, we concluded that CBR1 is a good molecular target for the development of anticancer drugs for HCC patients." @default.
• W2004851258 created "2016-06-24" @default.
• W2004851258 creator A5012945820 @default.
• W2004851258 creator A5018228034 @default.
• W2004851258 creator A5022844246 @default.
• W2004851258 creator A5040496951 @default.
• W2004851258 creator A5048784234 @default.
• W2004851258 creator A5048822545 @default.
• W2004851258 creator A5073499303 @default.
• W2004851258 creator A5079376363 @default.
• W2004851258 creator A5079976876 @default.
• W2004851258 creator A5087228268 @default.
• W2004851258 date "2011-02-01" @default.
• W2004851258 modified "2023-09-27" @default.
• W2004851258 title "Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells" @default.
• W2004851258 cites W155375556 @default.
• W2004851258 cites W1578283200 @default.
• W2004851258 cites W1967660686 @default.
• W2004851258 cites W1970060716 @default.
• W2004851258 cites W1980214543 @default.
• W2004851258 cites W1989448955 @default.
• W2004851258 cites W1999851592 @default.
• W2004851258 cites W2000175408 @default.
• W2004851258 cites W2010057452 @default.
• W2004851258 cites W2018520574 @default.
• W2004851258 cites W2037855793 @default.
• W2004851258 cites W2040031153 @default.
• W2004851258 cites W2051215275 @default.
• W2004851258 cites W2056688967 @default.
• W2004851258 cites W2080416537 @default.
• W2004851258 cites W2085609942 @default.
• W2004851258 cites W2094026727 @default.
• W2004851258 cites W2102526923 @default.
• W2004851258 cites W2103027363 @default.
• W2004851258 cites W2106885128 @default.
• W2004851258 cites W2108489423 @default.
• W2004851258 cites W2121153171 @default.
• W2004851258 cites W2121966499 @default.
• W2004851258 cites W2134240491 @default.
• W2004851258 cites W2135319921 @default.
• W2004851258 cites W2136659618 @default.
• W2004851258 cites W2137794530 @default.
• W2004851258 cites W2143343444 @default.
• W2004851258 cites W2144625075 @default.
• W2004851258 cites W2149960175 @default.
• W2004851258 cites W2154860856 @default.
• W2004851258 cites W2164277862 @default.
• W2004851258 cites W2166934143 @default.
• W2004851258 doi "https://doi.org/10.1016/j.jhep.2010.06.045" @default.
• W2004851258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21056497" @default.
• W2004851258 hasPublicationYear "2011" @default.
• W2004851258 type Work @default.
• W2004851258 sameAs 2004851258 @default.
• W2004851258 citedByCount "65" @default.
• W2004851258 countsByYear W20048512582012 @default.
• W2004851258 countsByYear W20048512582013 @default.
• W2004851258 countsByYear W20048512582014 @default.
• W2004851258 countsByYear W20048512582015 @default.
• W2004851258 countsByYear W20048512582016 @default.
• W2004851258 countsByYear W20048512582017 @default.
• W2004851258 countsByYear W20048512582018 @default.
• W2004851258 countsByYear W20048512582019 @default.
• W2004851258 countsByYear W20048512582020 @default.
• W2004851258 countsByYear W20048512582021 @default.
• W2004851258 countsByYear W20048512582022 @default.
• W2004851258 countsByYear W20048512582023 @default.
• W2004851258 crossrefType "journal-article" @default.
• W2004851258 hasAuthorship W2004851258A5012945820 @default.
• W2004851258 hasAuthorship W2004851258A5018228034 @default.
• W2004851258 hasAuthorship W2004851258A5022844246 @default.
• W2004851258 hasAuthorship W2004851258A5040496951 @default.
• W2004851258 hasAuthorship W2004851258A5048784234 @default.
• W2004851258 hasAuthorship W2004851258A5048822545 @default.
• W2004851258 hasAuthorship W2004851258A5073499303 @default.
• W2004851258 hasAuthorship W2004851258A5079376363 @default.
• W2004851258 hasAuthorship W2004851258A5079976876 @default.
• W2004851258 hasAuthorship W2004851258A5087228268 @default.
• W2004851258 hasConcept C126322002 @default.
• W2004851258 hasConcept C185592680 @default.
• W2004851258 hasConcept C190283241 @default.
• W2004851258 hasConcept C2776151105 @default.
• W2004851258 hasConcept C2776694085 @default.
• W2004851258 hasConcept C2778239845 @default.
• W2004851258 hasConcept C2781303535 @default.
• W2004851258 hasConcept C502942594 @default.
• W2004851258 hasConcept C55493867 @default.
• W2004851258 hasConcept C71924100 @default.
• W2004851258 hasConceptScore W2004851258C126322002 @default.
• W2004851258 hasConceptScore W2004851258C185592680 @default.
• W2004851258 hasConceptScore W2004851258C190283241 @default.
• W2004851258 hasConceptScore W2004851258C2776151105 @default.
• W2004851258 hasConceptScore W2004851258C2776694085 @default.
• W2004851258 hasConceptScore W2004851258C2778239845 @default.
• W2004851258 hasConceptScore W2004851258C2781303535 @default.
• W2004851258 hasConceptScore W2004851258C502942594 @default.
• W2004851258 hasConceptScore W2004851258C55493867 @default.
• W2004851258 hasConceptScore W2004851258C71924100 @default.
• W2004851258 hasIssue "2" @default.

• next